ME3221 is an angiotensin AT1 receptor antagonist with potent antihypertensive effects in rats with renal hypertension and spontaneously hypertensive rats (SHR), demonstrating efficacy comparable to or better than losartan; it produces sustained and stable blood pressure reduction without affecting heart rate, indicating its potential for the treatment of renal and essential hypertension.